Ikena Oncology (NASDAQ:IKNA) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ikena Oncology (NASDAQ:IKNA) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $4.00 price target on the stock.

Separately, Wedbush reaffirmed a “neutral” rating and set a $2.00 price target on shares of Ikena Oncology in a report on Thursday, November 7th.

Ikena Oncology Stock Performance

Shares of IKNA opened at $1.74 on Monday. Ikena Oncology has a 12 month low of $1.22 and a 12 month high of $2.32. The stock has a fifty day moving average price of $1.71 and a 200 day moving average price of $1.64.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08. On average, equities analysts forecast that Ikena Oncology will post -0.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Ikena Oncology

Institutional investors have recently bought and sold shares of the stock. Blue Owl Capital Holdings LP raised its position in shares of Ikena Oncology by 5.1% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company’s stock worth $6,750,000 after buying an additional 200,000 shares in the last quarter. BML Capital Management LLC raised its holdings in Ikena Oncology by 23.6% during the third quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after purchasing an additional 138,174 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Ikena Oncology by 813.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock valued at $729,000 after purchasing an additional 457,245 shares in the last quarter. Sofinnova Investments Inc. increased its position in shares of Ikena Oncology by 230.7% during the 2nd quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock valued at $631,000 after purchasing an additional 266,904 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Ikena Oncology by 15.2% in the 2nd quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock worth $536,000 after buying an additional 42,931 shares in the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.